Overview

NiraParib Maintenance After Carboplatin and Paclitaxel in optimaLly debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Status:
Not yet recruiting

Trial end date:
2030-10-01

Target enrollment:

Participant gender:

Summary

Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass following primary tumor debulking to determine recurrence free survival in patients treated with 3 cycles carboplatin + paclitaxel and maintenance therapy with niraparib vs. 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib.

Phase:

Phase 3

Details

Lead Sponsor:

North Eastern German Society of Gynaecological Oncology

Collaborator:

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest